ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

19 Dec 2024 16:25:09 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

18 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

12 Dec 2024 13:32:31 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

04 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 Nov 2024 05:30:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

11 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

24 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

23 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

10 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

09 Sep 2024 15:47:16 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

26 Aug 2024 08:29:15 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

09 Aug 2024 11:49:53 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

07 Aug 2024 08:01:10 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

06 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

28 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

30 Apr 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

03 Apr 2024 08:01:00 By Nasdaq GlobeNewswire